PD-L1 expression is typically detected using immunohistochemistry (IHC) assays on tumor tissue samples. These assays help determine the PD-L1 status of a tumor, which can be crucial for deciding treatment strategies, particularly when considering immunotherapy options. The threshold for what constitutes high versus low PD-L1 expression can vary, and the interpretation of results is often specific to the type of cancer being treated.
